1. 1) Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos., 30, 795–804 (2002).
2. 2) Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N. Engl. J. Med., 374, 94–95 (2016).
3. 3) Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N. Engl. J. Med., 382, 2289–2301 (2020).
4. 4) U.S. Food and Drug Administration. In vitro drug interaction studies—cytochrome p450 enzyme- and transporter-mediated drug interactions guidance for industry, U.S. Food and Drug Administration, Silver Spring, MD, U.S.A. (2020).
5. 5) U.S. Food and Drug Administration. Clinical drug interaction studies—cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, U.S. Food and Drug Administration, Silver Spring, MD, U.S.A. (2020).